New Appointment

Oxford Biomedica PLC
14 November 2002

For immediate release
14 November 2002



                        OXFORD BIOMEDICA PLC


     DAVID HIGGINS APPOINTED VICE PRESIDENT FOR BUSINESS DEVELOPMENT



Oxford, United Kingdom and San Diego, USA - 14 November 2002. Oxford BioMedica
plc announced today the appointment of Dr. David Higgins as Vice President for
Business Development. He has been appointed to Oxford BioMedica's San Diego
subsidiary to spearhead business development primarily in the USA. Dr. Higgins
has extensive experience in the biotech industry having worked in project
management and business development for Invitrogen Corporation, Chiron
Corporation and Idun Pharmaceuticals over the past 10 years.



Commenting on the appointment Chief Executive, Professor Alan Kingsman said

'We are delighted to have attracted Dave Higgins to Oxford BioMedica. His
experience of the North American pharmaceutical environment is an important part
of the Company's plans to market its products aggressively over the next 12
months'



                                     -Ends-


For further information, please contact:

Oxford BioMedica plc
Professor Alan Kingsman, Chief Executive                Tel: [phone]
 
City/Financial Enquiries:
Mike Wort, James Chandler: Beattie Financial            Tel: [phone]

Scientific/Trade Press Enquiries:
Sue Charles, Katja Stout: Charles Consultants           Tel: [phone]



Notes to Editors



1.       Oxford BioMedica plc


Established in 1995 as a spin out from Oxford University, Oxford BioMedica is an
international biotechnology company with a diverse portfolio of products and
technology, specialising in gene-based products and technology in the areas of
cancer, neurological disease, cardiovascular disease and blood disorders. This
is underpinned by over 70 patent families, about quarter of which are issued.
Oxford BioMedica plc was floated on the Alternative Investment Market of the
London Stock Exchange in December 1996, and was promoted to the United Kingdom
Listing Authority Official List in April 2001 following a successful £35.5
million fund-raising.



Oxford BioMedica is headquartered in Oxford, UK and has a wholly-owned
subsidiary in San Diego, USA



Currently Oxford BioMedica has corporate collaborations with Aventis, IDM,
Amersham, Valentis, Virbac and Wyeth. BioMedica has two products in Phase I/II
clinical trials: MetXia(R) for late-stage breast cancer, and TroVax(R) for
late-stage colorectal cancer.





2.       World Wide Web



Further information is available on the World Wide Web at http://
www.oxfordbiomedica.co.uk.






                      This information is provided by RNS
            The company news service from the London Stock Exchange